Evaluation of Liver Function

Initial Laboratory Evaluation

• The initial assessment of liver function should include a comprehensive panel of liver chemistry tests including serum levels of bilirubin, aspartate aminotransferase (AST), alanine transaminase (ALT), alkaline phosphatase (ALP), prothrombin time expressed as international normalized ratio (INR), albumin, and platelet count, as recommended by the National Comprehensive Cancer Network 1
• Elevated levels of aminotransferases (AST and ALT) indicate hepatocyte injury and necrosis, with ALT elevations being more specific for liver injury due to low concentrations in other tissues, according to the American College of Radiology 2
• The severity of aminotransferase elevation can be classified as mild (<5 times the upper reference limit), moderate (5-10 times the upper reference limit), or severe (>10 times the upper reference limit), as defined by the American College of Radiology 2
• The AST/ALT ratio can help distinguish alcoholic liver disease (ratio >2) from non-alcoholic fatty liver disease, as reported in the Journal of Hepatology 3
• Elevated alkaline phosphatase (ALP) levels are associated with cholestatic liver disease, which can occur with or without elevated bilirubin, according to the American College of Radiology 2
• Decreased albumin levels reflect the liver's synthetic capacity and suggest chronic liver disease, as stated by the American Gastroenterological Association 4 and the National Comprehensive Cancer Network 1
• Prolonged prothrombin time/INR measures clotting factors synthesized by the liver and indicates impaired synthetic function, as reported by the American Gastroenterological Association 4 and the National Comprehensive Cancer Network 1
• Elevated bilirubin levels may indicate various hepatobiliary disorders, according to the American Gastroenterological Association 4 and the Journal of Gastroenterology 5
• Thrombocytopenia, as indicated by a low platelet count, may suggest advanced liver disease, as stated by the National Comprehensive Cancer Network 1

Diagnostic Approach Based on Pattern of Abnormalities

• The initial evaluation of a hepatocellular pattern (predominant aminotransferase elevation) should exclude common hepatic diseases with noninvasive serologic tests, including hepatitis panel (HBsAg, hepatitis B surface antibody, HBcAb, HCV antibodies), as recommended by the National Comprehensive Cancer Network 1 and the American Gastroenterological Association 4
• Further evaluation for persistent or significant elevations should include additional serologic testing for autoimmune markers, iron studies, α1-antitrypsin, ceruloplasmin, and imaging studies (ultrasound, CT, or MRI), as reported by the American Gastroenterological Association 4 and the Journal of Gastroenterology 5
• The Child-Pugh classification incorporates laboratory measurements (albumin, bilirubin, prothrombin time) and clinical assessments (encephalopathy, ascites) to evaluate liver function, as stated by the National Comprehensive Cancer Network 1
• The MELD score uses bilirubin, creatinine, and INR to evaluate liver function and is originally developed for TIPS procedures, now used for liver transplant allocation, as reported by the National Comprehensive Cancer Network 1
• The Albumin-Bilirubin (ALBI) grade considers serum albumin and bilirubin levels and is helpful in predicting survival outcomes, according to the National Comprehensive Cancer Network 1 and the Journal of Hepatology 6

Advanced Assessment of Liver Function

• Simple fibrosis scores (FIB-4, NAFLD Fibrosis Score) are useful for initial risk stratification, as reported by the Journal of Hepatology 7
• Elastography techniques (FibroScan®, MR elastography) can quantify the degree of fibrosis, according to the National Comprehensive Cancer Network 1 and the Journal of Hepatology 7

Common Pitfalls in Liver Function Evaluation

• Normal values do not exclude liver disease, as 2.5% of healthy individuals will have abnormal elevation of a given liver chemistry test, as stated by the American Gastroenterological Association 4
• The spectrum effect should be considered when applying non-invasive tests to populations with risk factors for liver disease, as reported by the Journal of Hepatology 7
• Temporary events, such as renal failure or spontaneous bacterial peritonitis, may affect the assessment of liver function, according to the Journal of Hepatology 6

Liver Disease Diagnosis and Screening

Introduction to Liver Disease

• Liver disease can develop silently with no signs or symptoms until complications of liver failure or portal hypertension develop, and patients can progress through significant fibrosis to cirrhosis with persistently normal liver function tests (LFTs) 8
• The British Society of Gastroenterology states that liver enzymes may be normal or elevated in apoptotic diseases, including fatty liver disease, and the degree of abnormality is not related to the stage of progression from simple fatty liver to cirrhosis 8

Clinical Implications and Screening Approach

• The EASL guidelines on alcohol-related liver disease note that advanced liver fibrosis may present with normal LFTs 9
• When cirrhosis is suspected based on risk factors, such as chronic alcohol use or viral hepatitis, fibrosis assessment should be performed even if LFTs are normal, using non-invasive fibrosis scores like FIB-4 or NAFLD Fibrosis Score 9
• The American Association for the Study of Liver Diseases and the European Association for the Study of the Liver recommend calculating non-invasive fibrosis scores first, with values signifying low risk of advanced fibrosis, and proceeding to elastography if scores are indeterminate or elevated 8

Diagnostic Pitfalls to Avoid

• Normal LFTs alone should not be used to exclude cirrhosis in patients with risk factors for chronic liver disease, as stated by the American College of Gastroenterology 8, 9
• The degree of LFT elevation does not correlate with fibrosis stage, and standard LFTs are only 38% sensitive and 83% specific for detecting hepatic fibrosis, making them inadequate screening tools when used in isolation, according to the British Society of Gastroenterology 8, 10

Monitoring and Surveillance

• For patients with known risk factors but normal LFTs, the European Association for the Study of the Liver recommends performing elastography to detect occult fibrosis, screening for portal hypertension with platelet count and imaging, and considering upper endoscopy to assess for varices 8, 9, 10
• The American Association for the Study of Liver Diseases recommends initiating hepatocellular carcinoma surveillance if cirrhosis is confirmed, regardless of LFT values 8

Liver Function Test Interpretation in Adults

Pattern Recognition and Initial Assessment

• The American Gastroenterological Association recommends confirming hepatobiliary origin with GGT or ALP fractionation, as ALP can originate from bone, especially in post-menopausal women 11, 12
• Evaluate for biliary obstruction with imaging (ultrasound, CT, or MRI) and consider drug-induced cholestasis, primary biliary cholangitis, or primary sclerosing cholangitis 13, 14

Drug-Induced Liver Injury Detection

• The European Association for the Study of the Liver suggests initiating accelerated monitoring when ALT ≥5× ULN (if asymptomatic and bilirubin normal) 15
• Interrupt study drug when ALT ≥8× ULN with normal bilirubin, ALT ≥3× ULN with total bilirubin ≥2× baseline, or ALT ≥5× ULN with liver-related symptoms or immunologic reaction 11, 15

Essential History Elements for Interpretation

• The American Association for the Study of Liver Diseases recommends obtaining targeted information on metabolic risk factors, such as obesity, type 2 diabetes, and dyslipidemia, as well as family history of hemochromatosis or Wilson's disease 16
• Do not assume the magnitude of LFT elevation correlates with prognosis, as context and diagnosis matter more than absolute values 16

Laboratory Evaluation and Risk Stratification in Cirrhosis with Edema and Fatty Liver

Essential Laboratory Components

Interpretation of Liver Enzyme Levels

Portal Hypertension Assessment

Metabolic Evaluation in Fatty Liver Disease